Arcus Biosciences Future Growth
Future criteria checks 2/6
Arcus Biosciences is forecast to grow earnings and revenue by 15% and 21.1% per annum respectively. EPS is expected to grow by 21.7% per annum. Return on equity is forecast to be -117.6% in 3 years.
Key information
15.0%
Earnings growth rate
21.7%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 21.1% |
| Future return on equity | -117.6% |
| Analyst coverage | Good |
| Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Jan 07Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically
Nov 25Analysts Just Shaved Their Arcus Biosciences, Inc. (NYSE:RCUS) Forecasts Dramatically
Aug 08Need To Know: Analysts Are Much More Bullish On Arcus Biosciences, Inc. (NYSE:RCUS) Revenues
Jun 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 159 | -348 | -175 | -95 | 5 |
| 12/31/2025 | 164 | -382 | -302 | -342 | 9 |
| 12/31/2024 | 200 | -325 | -275 | -367 | 8 |
| 12/31/2023 | 117 | -307 | -330 | -306 | N/A |
| 9/30/2023 | 120 | -293 | -306 | -288 | N/A |
| 6/30/2023 | 121 | -287 | -316 | -306 | N/A |
| 3/31/2023 | 119 | -279 | -326 | -314 | N/A |
| 12/31/2022 | 112 | -267 | 426 | 438 | N/A |
| 9/30/2022 | 433 | 80 | 426 | 446 | N/A |
| 6/30/2022 | 409 | 67 | 447 | 473 | N/A |
| 3/31/2022 | 392 | 58 | 439 | 464 | N/A |
| 12/31/2021 | 383 | 53 | -282 | -256 | N/A |
| 9/30/2021 | 38 | -278 | -263 | -244 | N/A |
| 6/30/2021 | 93 | -199 | 14 | 26 | N/A |
| 3/31/2021 | 85 | -168 | 70 | 76 | N/A |
| 12/31/2020 | 78 | -123 | 108 | 111 | N/A |
| 9/30/2020 | 78 | -88 | 150 | 152 | N/A |
| 6/30/2020 | 15 | -112 | -93 | -92 | N/A |
| 3/31/2020 | 15 | -95 | -89 | -88 | N/A |
| 12/31/2019 | 15 | -85 | -75 | -73 | N/A |
| 9/30/2019 | 7 | -80 | -73 | -71 | N/A |
| 6/30/2019 | 9 | -69 | -58 | -55 | N/A |
| 3/31/2019 | 9 | -54 | -50 | -47 | N/A |
| 12/31/2018 | 8 | -50 | -47 | -43 | N/A |
| 9/30/2018 | 8 | -51 | -24 | -20 | N/A |
| 6/30/2018 | 4 | -63 | -36 | -33 | N/A |
| 3/31/2018 | 3 | -59 | -33 | -29 | N/A |
| 12/31/2017 | 1 | -53 | -31 | -25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RCUS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RCUS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RCUS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RCUS's revenue (21.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: RCUS's revenue (21.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RCUS is forecast to be unprofitable in 3 years.